The Pros and Cons of Ozempic/Semaglutide for Weight Loss

Ozempic, also known as semaglutide, is a drug approved by the Food and Drug Administration (FDA) to treat Type 2 diabetes. Despite the fact that it has been around for years, it has recently gained a lot of attention due to its use by celebrities for weight loss.[0] The drug, which is administered via injection, works by lowering the body’s blood sugar levels and increasing insulin sensitivity.[1]

What makes Ozempic so popular is its ability to help patients shed pounds quickly.[2] In 2021, the drug maker released a higher-dose version specifically for weight loss, which they named Wegovy.[3]

However, it is important to note that Ozempic isn’t approved for weight loss and can come with some side effects, such as nausea, vomiting, diarrhea, stomach (abdominal) pain, constipation, and possible thyroid tumors, including cancer.[4] There can also be a rebound weight gain once the drug is stopped and “Ozempic face.”[0] To maintain the weight loss, it must be taken indefinitely.[5]

The popularity of Ozempic and Wegovy as a weight loss drug has caused a shortage of the drug, which has been frustrating for many people who rely on it for medical reasons.[6] As a result, experts are raising concerns over the off-label use of the drug for weight loss.

In addition to the potential side effects, Ozempic is also expensive.[7] It costs $700 to $1,200 per month and Wegovy can cost up to $1,500 when not covered by insurance.[8]

Semaglutide has a role to play in assisting weight loss for people struggling with their weight, but it’s not a magical cure.[7] To get the most out of it, it must be taken with a commitment to lifestyle changes, such as healthier eating habits and more exercise, or else the weight will come back.[9]

Ultimately, it is important to remember that Ozempic is a diabetes drug and not a weight loss drug. It activates GLP-1 receptors in the body, which improves insulin function and helps with blood glucose levels.[9] It is essential to consult a doctor before taking Ozempic or Wegovy, to make sure it is the right drug for you.

0. “Ozempic's off-label use creates buzz beyond Hollywood” MD Linx, 21 Feb. 2023, https://www.mdlinx.com/article/-ozempics-off-label-use-creates-buzz-beyond-hollywood/1nUYdJyAcfgGr81k3coG4p

1. “Ozempic: Popular for all the wrong reasons” The Trinitonian, 23 Feb. 2023, https://trinitonian.com/2023/02/23/ozempic-popular-for-all-the-wrong-reasons/

2. “Ozempic as a weight loss drug: Is it for everybody?” WGN TV Chicago, 20 Feb. 2023, https://wgntv.com/news/medical-watch/ozempic-as-a-weight-loss-drug-is-it-for-everybody/

3. “Ozempic 411: For Weight Loss, Diabetes, or Both?” Plus, 1 Mar. 2023, https://www.hivplusmag.com/medications/ozempic-411-for-weight-loss-diabetes-or-both

4. “Type 2 diabetes patients struggle to find Ozempic as demand rises for its weight loss properties” KIRO Seattle, 20 Feb. 2023, https://www.kiro7.com/news/jesse-jones/type-2-diabetes-patients-struggle-find-ozempic-demand-rises-its-weight-loss-properties/D4DDMLL6EJHYJO2ZL2KXXTAEUY

5. “What the Ozempic Obsession Misses About Food and Health” TIME, 21 Feb. 2023, https://time.com/6256680/ozempic-obsession-weight-loss-food-health

6. “Popularity of Ozempic weight loss trend frustrates diabetic patients” Houston Chronicle , 27 Feb. 2023, https://www.houstonchronicle.com/lifestyle/renew-houston/article/diabetes-ozempic-shortage-weight-loss-17799642.php

7. “What Foods to Avoid When Taking Ozempic (Semaglutide) | HealthNews” Healthnews.com, 1 Mar. 2023, https://healthnews.com/family-health/drugs/ozempic-semaglutide-foods-to-avoid/

8. “Weight loss trends create shortage of diabetes medicine” WNEM, 23 Feb. 2023, https://www.wnem.com/2023/02/23/weight-loss-trends-create-shortage-diabetes-medicine

9. “Is Ozempic actually safe for overweight mums?” Kidspot, 1 Mar. 2023, https://www.kidspot.com.au/lifestyle/family-health/ozempic-leads-to-great-weight-loss-why-wouldnt-we-give-mums-a-helping-hand/news-story/cafb52caec222d9e4244c1184deeaf8d

Click Here to Leave a Comment Below 0 comments